How to Decide Which Anticoagulant to Use
For atrial fibrillation patients, prescribe a direct oral anticoagulant (DOAC)—apixaban, dabigatran, edoxaban, or rivaroxaban—unless the patient has a mechanical heart valve or moderate-to-severe mitral stenosis, in which case use warfarin. 1, 2
Step 1: Determine If Anticoagulation Is Needed
Calculate the CHA2DS2-VASc score to assess stroke risk 2:
- Score 0 (men) or 1 (women): Omit anticoagulation
- Score 1 (men) or 2 (women): Consider anticoagulation 1
- Score ≥2 (men) or ≥3 (women): Anticoagulation recommended 1, 2
This applies regardless of whether AF is paroxysmal, persistent, or permanent 2.
Step 2: Identify Absolute Contraindications to DOACs
Use warfarin (INR 2.0-3.0) instead of DOACs if the patient has 1, 2, 3:
- Mechanical heart valves (DOACs are contraindicated—less efficacious and less safe)
- Moderate-to-severe mitral stenosis (rheumatic heart disease)
- Thrombotic antiphospholipid syndrome (DOACs inferior to warfarin)
Note: Patients with bioprosthetic valves can receive DOACs 2.
Step 3: Assess Renal Function
Check creatinine clearance (CrCl) before prescribing 2, 4:
End-stage CKD (CrCl <15 mL/min) or dialysis: Use warfarin or apixaban (may be reasonable) 2. Other DOACs lack sufficient evidence in this population 3.
Moderate-to-severe CKD: Use dose-reduced DOACs 2:
- Apixaban: Reduce if serum creatinine ≥1.5 mg/dL
- Dabigatran: Reduce if CrCl 15-30 mL/min
- Rivaroxaban: Reduce if CrCl ≤50 mL/min
- Edoxaban: Reduce if CrCl 15-50 mL/min
Reevaluate renal and hepatic function at least annually 2.
Step 4: Choose Between DOACs and Warfarin
DOACs are preferred over warfarin because they 1, 2:
- Are at least noninferior (often superior) for preventing stroke
- Significantly reduce intracranial hemorrhage risk
- Require no routine INR monitoring
- Have fewer drug-food interactions
Switch from warfarin to a DOAC if 1:
- Risk of intracranial hemorrhage is elevated
- Poor INR control (time in therapeutic range <70%)
Continue warfarin if 2:
- Patient cannot maintain therapeutic INR with warfarin but has mechanical valve or severe mitral stenosis
- Patient preference after shared decision-making
Step 5: Select the Specific DOAC
All four DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are acceptable first-line choices 1, 2. No direct comparative trials show one is definitively superior 5.
Consider individual patient factors 5:
- Renal impairment: Apixaban has the least renal excretion
- GI bleeding history: Dabigatran and rivaroxaban may increase GI bleeding risk 4
- Twice-daily dosing tolerance: Apixaban and dabigatran require BID dosing; rivaroxaban and edoxaban are once daily
- Drug interactions: Consider hepatic metabolism pathways
Use full standard doses unless specific dose-reduction criteria are met 1.
Step 6: Address Bleeding Risk
Assess bleeding risk using HAS-BLED or similar validated tools at each visit 6, but do not use bleeding risk scores to withhold anticoagulation 1. Instead, modify risk factors:
- Control hypertension
- Avoid NSAIDs and antiplatelet agents (unless acute vascular event) 1
- Limit alcohol intake
- Correct anemia
Special Situations Where DOAC Efficacy Is Uncertain
Consider warfarin or consult specialist for 3:
- Left ventricular thrombus
- Catheter-associated DVT
- Cerebral venous sinus thrombosis
- Active cancer with VTE (though emerging evidence supports DOACs) 6
Reversal Agents Available
For life-threatening bleeding 4, 6:
- Dabigatran: Idarucizumab
- Apixaban/Rivaroxaban: Andexanet alfa
- If reversal agents unavailable: 4-factor prothrombin complex concentrate
Common Pitfalls to Avoid
- Don't underdose DOACs without meeting specific criteria—this increases stroke risk without reducing bleeding 1
- Don't combine anticoagulants with antiplatelet therapy routinely—only for acute vascular events 1
- Don't use DOACs in mechanical valves—this is associated with worse outcomes 3
- Don't forget to reassess stroke and bleeding risk periodically 2